×

Alnylam Pharma Submits MAA To EMA For Vutrisiran For Hereditary ATTR Amyloidosis With Polyneuropathy

Published Sep 13 2021 at 11:29 AM GMT
Key
Points
  • (RTTNews) - RNAi therapeutics company Alnylam Pharmaceuticals, Inc.
  • (ALNY) announced Monday the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with.




Trending

Stats

  • Published Sep 13, 2021 11:29 AM GMT